医学
帕妥珠单抗
内科学
曲妥珠单抗
临床终点
不利影响
肿瘤科
实体瘤疗效评价标准
贫血
队列
危险系数
癌症
进行性疾病
临床试验
置信区间
乳腺癌
疾病
作者
Timothy Lewis Cannon,Michael Rothe,Pam K. Mangat,Elizabeth Garrett‐Mayer,Vi K. Chiu,Jimmy J. Hwang,Namrata Vijayvergia,Olatunji B. Alese,Elie G. Dib,Herbert L. Duvivier,Kelsey Klute,Vaibhav Sahai,Eugene R. Ahn,Pablo M. Bedano,Deepti Behl,Sarah Sinclair,Ramya Thota,Walter J. Urba,Eddy S. Yang,Gina N. Grantham
摘要
Pertuzumab plus trastuzumab met prespecified criteria to declare a signal of activity in patients with BTC and ERBB2/3 amplification, overexpression, or mutation.
科研通智能强力驱动
Strongly Powered by AbleSci AI